Published in J Clin Oncol on November 10, 2008
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol (2014) 3.93
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol (2015) 1.56
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol (2011) 1.45
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol (2011) 1.43
Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2014) 1.28
Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol (2013) 1.20
Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol (2013) 1.12
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist (2011) 1.06
Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. J Thorac Dis (2011) 0.98
Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. Oncologist (2010) 0.96
Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer. Cancer Res Treat (2011) 0.93
The importance of multidisciplinary team management of patients with non-small-cell lung cancer. Curr Oncol (2012) 0.91
Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist (2012) 0.91
Radiation dose effect in locally advanced non-small cell lung cancer. J Thorac Dis (2014) 0.87
Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer. Cancer J (2013) 0.86
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Cancer Med (2013) 0.86
EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomark Res (2013) 0.85
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol (2013) 0.84
Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol (2017) 0.84
Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer (2015) 0.80
Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. Lung Cancer (2016) 0.79
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer (2015) 0.79
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. Front Oncol (2012) 0.78
L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. J Thorac Dis (2014) 0.77
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol (2011) 0.77
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI). Cancer Chemother Pharmacol (2012) 0.76
Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer (2013) 0.76
Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases. BMC Cancer (2015) 0.76
A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer. J Thorac Oncol (2014) 0.76
Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line? Transl Lung Cancer Res (2016) 0.76
Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. Springerplus (2015) 0.76
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.76
Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clin Lung Cancer (2016) 0.75
Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer. Front Oncol (2011) 0.75
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer (2013) 0.75
Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM. J Thorac Dis (2016) 0.75
State of the art of radiotherapy. Transl Lung Cancer Res (2013) 0.75
A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer. Clin Lung Cancer (2013) 0.75
Rare occurrence of cavitation of lung metastases following effective targeted therapy: A case report. Oncol Lett (2016) 0.75
Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients? J Thorac Dis (2014) 0.75
Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. Mol Clin Oncol (2014) 0.75
Continuous Activity Monitoring During Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys (2016) 0.75
Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience. Med Sci Monit (2015) 0.75
Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist? Nat Rev Clin Oncol (2010) 0.75
Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. Lung Cancer (Auckl) (2010) 0.75
Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations. Front Oncol (2013) 0.75
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer. Radiat Oncol (2014) 0.75
Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies. PLoS One (2016) 0.75
Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis. Mol Clin Oncol (2016) 0.75
A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. Ther Adv Med Oncol (2013) 0.75
Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision. Radiat Oncol J (2017) 0.75
The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis. Int J Clin Oncol (2016) 0.75
A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease. World J Oncol (2015) 0.75
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. Am J Clin Oncol (2016) 0.75
Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? Front Oncol (2017) 0.75
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol (2006) 8.15
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol (2007) 7.67
Lung cancer in never smokers: a review. J Clin Oncol (2007) 5.49
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS. J Clin Oncol (2009) 4.53
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology (2002) 3.91
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol (2003) 3.58
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
Lung cancer in 'Never-smokers': a unique entity. Oncology (Williston Park) (2010) 2.95
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol (2002) 2.78
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest (2003) 2.60
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol (2013) 2.27
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
DGIdb: mining the druggable genome. Nat Methods (2013) 2.26
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma. Oncology (Williston Park) (2013) 2.16
Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol (2011) 2.15
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. J Clin Oncol (2010) 2.00
The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials. PLoS Med (2012) 1.93
Differential prognostic impact of comorbidity. J Clin Oncol (2004) 1.92
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res (2007) 1.91
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol (2009) 1.90
"Wamepotea" (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr (2011) 1.87
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol (2006) 1.84
Adjusting mortality for loss to follow-up: analysis of five ART programmes in sub-Saharan Africa. PLoS One (2010) 1.84
Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr (2013) 1.82
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer (2014) 1.76
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer (2005) 1.76
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol (2011) 1.76
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website. J Thorac Oncol (2010) 1.65
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma (2009) 1.65
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys (2010) 1.64
Dynamic reprogramming of chromatin accessibility during Drosophila embryo development. Genome Biol (2011) 1.61
Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol (2010) 1.58
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol (2006) 1.56
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol (2012) 1.55
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry (2009) 1.55
Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol (2007) 1.55
Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer (2007) 1.54
A prospective randomized trial of 1 versus 2 injections during EUS-guided celiac plexus block for chronic pancreatitis pain. Gastrointest Endosc (2009) 1.52
To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med (2011) 1.52
Endoscopic ultrasound in non-small cell lung cancer and negative mediastinum on computed tomography. Am J Respir Crit Care Med (2004) 1.49
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost (2010) 1.47
Influenza vaccination in patients with cancer: an overview. Oncology (Williston Park) (2010) 1.44
Esophageal carcinoma with celiac nodal metastases; curative or palliative? J Thorac Oncol (2008) 1.44
MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis (2012) 1.40
Endoscopic transventricular selective amygdalohippocampectomy: cadaveric demonstration of a new operative approach. World Neurosurg (2012) 1.40
The sensitivity of lipid domains to small perturbations demonstrated by the effect of Triton. J Mol Biol (2003) 1.40
Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report. Lung Cancer (2006) 1.40
A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.39
Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leuk Res (2004) 1.39
The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol (2008) 1.38
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol (2010) 1.37
Who is the research subject in cluster randomized trials in health research? Trials (2011) 1.36
Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol (2010) 1.33
When is informed consent required in cluster randomized trials in health research? Trials (2011) 1.33
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res (2007) 1.32
The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer (2004) 1.32
A survey of Internet utilization among patients with cancer. Support Care Cancer (2010) 1.32
Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol (2007) 1.31
Quantification of accuracy and precision of multi-center DTI measurements: a diffusion phantom and human brain study. Neuroimage (2011) 1.30
Mothers' reports of postpartum pain associated with vaginal and cesarean deliveries: results of a national survey. Birth (2008) 1.30
Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol (2008) 1.28
Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol (2012) 1.27
Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.26
Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol (2014) 1.25
A prospective, randomized study of EUS-guided celiac plexus neurolysis for pancreatic cancer: one injection or two? Gastrointest Endosc (2011) 1.25
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol (2011) 1.24
Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol (2009) 1.24
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys (2010) 1.24
Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS (2004) 1.23
Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol (2010) 1.22